Systematic Review of Utility Values Used in the Pharmacoeconomic Evaluations for Schizophrenia: Implications on Cost-Effectiveness Results

Background and Objectives: Utility elicitation studies for schizophrenia generate different utility values for the same health states. We reviewed utility values used in schizophrenia pharmacoeconomic evaluations and evaluated the impact of their selection on the incremental cost-effectiveness ratio (ICER). Methods: A systematic search was performed in Medline and Embase. Health state definitions, associated utility values, elicitation studies, and value selection processes were extracted. Sets of utility values for all schizophrenia health states were used in a cost-effectiveness model to evaluate the ICER. Results: Thirty-five cost-utility analyses (CUAs) referring to 11 utility elicitation studies were included. The most frequent health states were ‘stable’ (28 CUAs, 7 utility elicitation studies, 10 values, value range 0.650–0.919), ‘relapse requiring hospitalisation’ (18, 5, 7, 0.270–0.604), ‘relapse not requiring hospitalisation’ (18, 5, 10, 0.460–0.762), and ‘relapse only’ (10, 5, 6, 0.498–0.700). Seventeen sets of utility values were identified with difference in utility values between relapse and stable ranging from −0.358 to −0.050, resulting in ICERs ranging from −56.2% to +222.6% from average. Conclusion: The use of utility values for schizophrenia health states differs among CUAs and impacts on the ICER. More rigorous and transparent use of utility values and sensitivity analysis with different sets of utility values are suggested for future CUAs.